beta

ANIK

Anika Therapeutics Inc.

Anik

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

10-24-2018 after market close 07-25-2018 after market close 05-02-2018 after market close 02-21-2018 after market close 10-25-2017 after market close 07-26-2017 after market close 05-03-2017 after market close
Actual EPS 0.53 0.68 0.11 0.38 0.46 0.76 0.37
Consensus EPS 0.34 0.29 0.25 0.41 0.41 0.45 0.38
Estimated EPS 0.34 0.29 0.25 0.41 0.41 0.45 0.38
Number of Estimates 2 2 2 2 2 2 2
EPS Surprise $0.19 $0.39 -$0.14 -$0.03 $0.05 $0.31 -$0.01

Stats

Summary

Anika Therapeutics Inc develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair.

Market Cap: 994 Million

Primary Exchange: Nasdaq Global Select

Website: http://www.anikatherapeutics.com

Shares Outstanding: 14.7 Million

Float: 14.1 Million

Dividend: 0.0 (0.0%)

Beta: 1.633997

Sector: Healthcare

Industry: Biotechnology

Short Interest (Jan 12, 2018): 1.3 Million

Ethical Flags

Animal testing

Longest drawdown: 490 trading days

From: 2014-07-14 To: 2016-06-22

Lowest Point:

Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan

via: Business Wire at 2018-12-12 08:00:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST… read more...

Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan

via: Business Wire at 2018-12-12 08:00:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST… read more...

Anika to Showcase HYALOFAST at the International Cartilage Regeneration and Joint Preservation Society (ICRS) Focus Meeting in Milan

via: Business Wire at 2018-12-12 08:00:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its entire Orthobiologics franchise, including HYALOFAST… read more...

Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

via: Business Wire at 2018-12-04 16:05:00:000

Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology … read more...

Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

via: Business Wire at 2018-12-04 16:05:00:000

Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology … read more...

Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

via: Business Wire at 2018-12-04 16:05:00:000

Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology … read more...

Anika Resumes Global Distribution of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX

via: Business Wire at 2018-12-04 16:05:00:000

Company Expands HYALOFAST Commercial Reach in Asia, the Middle East and Latin America Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology … read more...

Anika Therapeutics Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-25 13:36:17:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Anika Therapeutics Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-25 13:36:17:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Anika Therapeutics Inc. 2018 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-10-25 13:36:17:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q3 earnings Read more … read more...

Anika Therapeutics, Inc. (ANIK) CEO Joseph Darling on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-24 21:42:04:000

Anika Therapeutics, Inc. (ANIK) Q3 2018 Results Earnings Conference Call October 24, 2018 05:00 PM ET Executives Sylvia Cheung - CFO Joseph Darling - President and CEO Analysts Mike Petusky - Barrington Research Joe Munda - First Analysis Jim Sidoti - Sidoti & Company… read more...

Anika Therapeutics, Inc. (ANIK) CEO Joseph Darling on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-24 21:42:04:000

Anika Therapeutics, Inc. (ANIK) Q3 2018 Results Earnings Conference Call October 24, 2018 05:00 PM ET Executives Sylvia Cheung - CFO Joseph Darling - President and CEO Analysts Mike Petusky - Barrington Research Joe Munda - First Analysis Jim Sidoti - Sidoti & Company… read more...

Anika Therapeutics, Inc. (ANIK) CEO Joseph Darling on Q3 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-10-24 21:42:04:000

Anika Therapeutics, Inc. (ANIK) Q3 2018 Results Earnings Conference Call October 24, 2018 05:00 PM ET Executives Sylvia Cheung - CFO Joseph Darling - President and CEO Analysts Mike Petusky - Barrington Research Joe Munda - First Analysis Jim Sidoti - Sidoti & Company… read more...

Anika Therapeutics Q3 top line off 2%; earnings up 10%

via: SeekingAlpha at 2018-10-24 16:44:49:000

Anika Therapeutics (NASDAQ: ANIK ) Q3 results ($M): Revenue: 26.8 (-1.5%); Orthobiologics: 24.1 (+0.4%). More news on: Anika Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...

Anika Therapeutics beats by $0.22, misses on revenue

via: SeekingAlpha at 2018-10-24 16:13:13:000

Anika Therapeutics (NASDAQ: ANIK ): Q3 GAAP EPS of $0.53 beats by $0.22. More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Anika Reports Third Quarter 2018 Financial Results

via: Business Wire at 2018-10-24 16:05:00:000

CINGAL Drives Strong International Viscosupplement Revenue Growth Achieves Solid Bottom Line Performance with $0.53 Diluted EPS Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on i… read more...

Susan Vogt Appointed to Board of Directors of Anika Therapeutics

via: Business Wire at 2018-10-24 08:30:00:000

Long-Serving Director Steven Wheeler to Retire from Board in February 2019 Anika Therapeutics, Inc. (NASDAQ: ANIK) (Anika or the Company), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its p… read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2018-10-23 17:35:30:000

ABX , AEM , AFL , AGNC , AHL , AKR , ALGN , ALGT , AMD , ANIK , ARI , ASGN , AX , AXS , AZPN , BHE , CCMP , CLB , CLGX , CLS , CMRE , CTXS , CUZ , CVBF , CVRR , DLB , DRE , ECHO , EFX , EIG , ELY , EQC , ETH , F , FFIV , FNF , FR , FTI , FWRD , GG , … read more...

Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24

via: Business Wire at 2018-10-10 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day, Wednesday, October 24, 2018, at 5:00 p.m. ET … read more...

Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24

via: Business Wire at 2018-10-10 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day, Wednesday, October 24, 2018, at 5:00 p.m. ET … read more...

Anika to Issue Third-Quarter 2018 Financial Results and Business Highlights on Wednesday, October 24

via: Business Wire at 2018-10-10 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day, Wednesday, October 24, 2018, at 5:00 p.m. ET … read more...

Anika Therapeutics Is A Solid Buy In October 2018

via: SeekingAlpha at 2018-10-01 14:11:43:000

Based in Bedford, Massachusetts, Anika Therapeutics ( ANIK ), a global orthopedic and regenerative medicine company, has not proved to be the best of investments in H1 2018. This company, which mainly bases its products on its proprietary hyaluronic acid technology, has reported last one year … read more...

Anika Therapeutics Is A Solid Buy In October 2018

via: SeekingAlpha at 2018-10-01 14:11:43:000

Based in Bedford, Massachusetts, Anika Therapeutics ( ANIK ), a global orthopedic and regenerative medicine company, has not proved to be the best of investments in H1 2018. This company, which mainly bases its products on its proprietary hyaluronic acid technology, has reported last one year … read more...

Anika Therapeutics Is A Solid Buy In October 2018

via: SeekingAlpha at 2018-10-01 14:11:43:000

Based in Bedford, Massachusetts, Anika Therapeutics ( ANIK ), a global orthopedic and regenerative medicine company, has not proved to be the best of investments in H1 2018. This company, which mainly bases its products on its proprietary hyaluronic acid technology, has reported last one year … read more...

Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018

via: Business Wire at 2018-09-05 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief Executive Officer, Joseph Darling, and Chief F… read more...

Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors

via: Business Wire at 2018-09-05 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) (Anika or the Company), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that Che… read more...

Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018

via: Business Wire at 2018-09-05 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief Executive Officer, Joseph Darling, and Chief F… read more...

Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors

via: Business Wire at 2018-09-05 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) (Anika or the Company), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that Che… read more...

Anika to Participate in the 2018 Morgan Stanley Global Healthcare Conference on September 12, 2018

via: Business Wire at 2018-09-05 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief Executive Officer, Joseph Darling, and Chief F… read more...

Anika Appoints Dr. Cheryl Blanchard to Its Board of Directors

via: Business Wire at 2018-09-05 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) (Anika or the Company), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that Che… read more...

Singular Research EPS Surprises For Q2 2018

via: SeekingAlpha at 2018-09-04 13:17:09:000

Earnings Surprises and Disappointments for Q2 2018 Top Surprises JMP Group LLC ( JMP ) +256% JMP data by YCharts Had record investment banking revenues Increased accumulation of loans leading up to the CLO V pricing Had a favorable exit from a principal investment Inves… read more...

Anika Therapeutics: Strong Earnings Coupled With Improving Prospects

via: SeekingAlpha at 2018-08-02 05:25:00:000

If we become increasingly humble about how little we know, we may be more eager to search. - Sir John Templeton Anika Therapeutics (NASDAQ: ANIK ) is a highly interesting company, and one of our core holdings in the long-term (CP-Alpha) portfolio of Integrated BioSci Investing. Despite t… read more...

Anika Therapeutics: Strong Earnings Coupled With Improving Prospects

via: SeekingAlpha at 2018-08-02 05:25:00:000

If we become increasingly humble about how little we know, we may be more eager to search. - Sir John Templeton Anika Therapeutics (NASDAQ: ANIK ) is a highly interesting company, and one of our core holdings in the long-term (CP-Alpha) portfolio of Integrated BioSci Investing. Despite t… read more...

Anika Therapeutics: Strong Earnings Coupled With Improving Prospects

via: SeekingAlpha at 2018-08-02 05:25:00:000

If we become increasingly humble about how little we know, we may be more eager to search. - Sir John Templeton Anika Therapeutics (NASDAQ: ANIK ) is a highly interesting company, and one of our core holdings in the long-term (CP-Alpha) portfolio of Integrated BioSci Investing. Despite t… read more...

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 14:59:12:000

Anika Therapeutics Inc. (ANIK) Q2 2018 Earnings Conference Call July 26, 2018 09:00 AM ET Executives Sylvia Cheung - Chief Financial Officer Joseph Darling - President and Chief Executive Officer Analysts Joe Munda - First Analysis Lisa Springer - Singular Research Jim Si… read more...

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 14:59:12:000

Anika Therapeutics Inc. (ANIK) Q2 2018 Earnings Conference Call July 26, 2018 09:00 AM ET Executives Sylvia Cheung - Chief Financial Officer Joseph Darling - President and Chief Executive Officer Analysts Joe Munda - First Analysis Lisa Springer - Singular Research Jim Si… read more...

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q2 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-07-26 14:59:12:000

Anika Therapeutics Inc. (ANIK) Q2 2018 Earnings Conference Call July 26, 2018 09:00 AM ET Executives Sylvia Cheung - Chief Financial Officer Joseph Darling - President and Chief Executive Officer Analysts Joe Munda - First Analysis Lisa Springer - Singular Research Jim Si… read more...

Anika up 18% after Q2 beat

via: SeekingAlpha at 2018-07-26 13:26:32:000

Thinly traded Anika Therapeutics ( ANIK +17.6% ) is up on almost 75% higher volume, albeit on turnover of only 480K shares, on the heels of its Q2 results released yesterday after the close. More news on: Anika Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read mor… read more...

Anika up 18% after Q2 beat

via: SeekingAlpha at 2018-07-26 13:26:32:000

Thinly traded Anika Therapeutics ( ANIK +17.6% ) is up on almost 75% higher volume, albeit on turnover of only 480K shares, on the heels of its Q2 results released yesterday after the close. More news on: Anika Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read mor… read more...

Anika up 18% after Q2 beat

via: SeekingAlpha at 2018-07-26 13:26:32:000

Thinly traded Anika Therapeutics ( ANIK +17.6% ) is up on almost 75% higher volume, albeit on turnover of only 480K shares, on the heels of its Q2 results released yesterday after the close. More news on: Anika Therapeutics Inc., Healthcare stocks news, Stocks on the move, Read mor… read more...

Midday Gainers / Losers (07/26/2018)

via: SeekingAlpha at 2018-07-26 12:40:18:000

Gainers: BSPM +105% . SVU +64% . BPI +50% . PCMI +26% . JBT +22% . AWX +20% . ANIK +18% . MTSL +15% . ADMA +17% . KODK +17% . More news on: Biostar Pharmaceutic, SUPERVALU Inc., Bridgepoint Education, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (07/26/2018)

via: SeekingAlpha at 2018-07-26 12:40:18:000

Gainers: BSPM +105% . SVU +64% . BPI +50% . PCMI +26% . JBT +22% . AWX +20% . ANIK +18% . MTSL +15% . ADMA +17% . KODK +17% . More news on: Biostar Pharmaceutic, SUPERVALU Inc., Bridgepoint Education, Inc., Stocks on the move, , Read more … read more...

Midday Gainers / Losers (07/26/2018)

via: SeekingAlpha at 2018-07-26 12:40:18:000

Gainers: BSPM +105% . SVU +64% . BPI +50% . PCMI +26% . JBT +22% . AWX +20% . ANIK +18% . MTSL +15% . ADMA +17% . KODK +17% . More news on: Biostar Pharmaceutic, SUPERVALU Inc., Bridgepoint Education, Inc., Stocks on the move, , Read more … read more...

Anika Therapeutics Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 12:36:00:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Anika Therapeutics Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 12:36:00:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Anika Therapeutics Inc. 2018 Q2 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-07-26 12:36:00:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q2 earnings Read more … read more...

Anika Therapeutics beats by $0.35, beats on revenue

via: SeekingAlpha at 2018-07-25 16:08:26:000

Anika Therapeutics (NASDAQ: ANIK ): Q2 EPS of $0.68 beats by $0.35 . More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Anika Reports Second Quarter 2018 Financial Results

via: Business Wire at 2018-07-25 16:05:00:000

Solid Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Diluted EPS New Leadership Added to Optimize Commercial Reach and Operating Efficiency Multiple Initiatives Ongoing to Gain U.S. Regulatory Approval of CINGAL Anika Therapeutics, Inc. (NASDAQ: A… read more...

Notable earnings after Wednesday's close

via: SeekingAlpha at 2018-07-24 17:35:22:000

ABX , AEM , AGNC , ALGN , ALGT , AMD , ANIK , ARI , ASGN , AXS , AXTI , BEAT , BPI , CCJ , CCMP , CDE , CHE , CLB , CLGX , CTXS , CUBI , CUZ , CVRR , CW , DDR , DLB , DRE , ECHO , EFX , EHC , EIG , ESRT , ESV , ETH , F , FARO , FB , FCPT , FFIV , FOE … read more...

Anika to Issue Second-Quarter 2018 Financial Results and Business Highlights on Wednesday, July 25

via: Business Wire at 2018-07-11 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July 26, 2018, at 9:00 a.m. ET to discuss its fi… read more...

Anika to Issue Second-Quarter 2018 Financial Results and Business Highlights on Wednesday, July 25

via: Business Wire at 2018-07-11 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July 26, 2018, at 9:00 a.m. ET to discuss its fi… read more...

Anika to Issue Second-Quarter 2018 Financial Results and Business Highlights on Wednesday, July 25

via: Business Wire at 2018-07-11 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July 26, 2018, at 9:00 a.m. ET to discuss its fi… read more...

Biotech Analysis Central Pharma News: CytoDyn's BLA Update, Anika's Failure, Vertex's Expansion Of Facility

via: SeekingAlpha at 2018-06-25 12:36:18:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. CytoDyn Updates Progress Of HIV Combination Therapy BLA With The FDA News: Recently, CytoDyn ( CYDY ) announced an update for its Pro-140 combinati… read more...

Biotech Analysis Central Pharma News: CytoDyn's BLA Update, Anika's Failure, Vertex's Expansion Of Facility

via: SeekingAlpha at 2018-06-25 12:36:18:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. CytoDyn Updates Progress Of HIV Combination Therapy BLA With The FDA News: Recently, CytoDyn ( CYDY ) announced an update for its Pro-140 combinati… read more...

Biotech Analysis Central Pharma News: CytoDyn's BLA Update, Anika's Failure, Vertex's Expansion Of Facility

via: SeekingAlpha at 2018-06-25 12:36:18:000

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. CytoDyn Updates Progress Of HIV Combination Therapy BLA With The FDA News: Recently, CytoDyn ( CYDY ) announced an update for its Pro-140 combinati… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges

via: SeekingAlpha at 2018-06-21 08:00:00:000

Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin… read more...

Midday Gainers / Losers (06/20/2018)

via: SeekingAlpha at 2018-06-20 12:50:22:000

Gainers: OTCPK:LFIN +40% . ADOM +38% . AETI +35% . CLBS +32% . FUV +26% . FORD +25% . DAC +24% . CLPS +24% . I +23% . LBIX +17% . More news on: LongFin Corp.A, ADOMANI, Inc., American Electric Technologies, Inc., Stocks on the move, , Read more … read more...

Premarket analyst action - healthcare

via: SeekingAlpha at 2018-06-20 08:18:57:000

Sangamo Therapeutics (NASDAQ: SGMO ) initiated with Buy rating and $24 (46% upside) price target at BofA/Merrill Lynch. Shares up 3% premarket. More news on: Sangamo Therapeutics, Inc., PTC Therapeutics, Anika Therapeutics Inc., Healthcare stocks news, Stocks on the move, , … read more...

Anika Therapeutics' CINGAL flunks late-stage knee osteoarthritis study; shares down 21% after hours

via: SeekingAlpha at 2018-06-19 16:44:09:000

Thinly traded Anika Therapeutics (NASDAQ: ANIK ) slumps 21% after hours in response to its announcement that a Phase 3 clinical trial, 16-02, evaluating CINGAL for the treatment of knee osteoarthritis failed to achieve the primary endpoint. Specifically, treatment with CINGAL f… read more...

Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee Osteoarthritis

via: Business Wire at 2018-06-19 16:05:00:000

CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. approval Strong pain reduction and overall symptom relief consistent with statistically significant … read more...

Your Daily Pharma Scoop: Recent IPO And Offerings Review

via: SeekingAlpha at 2018-05-31 04:02:59:000

IPO As a general rule, we dont invest in IPOs. It is too risky. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs. But many people like dreams, so when an IPO gets launched - assuming theres enough hype - the stock soars f… read more...

Your Daily Pharma Scoop: Recent IPO And Offerings Review

via: SeekingAlpha at 2018-05-31 04:02:59:000

IPO As a general rule, we dont invest in IPOs. It is too risky. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs. But many people like dreams, so when an IPO gets launched - assuming theres enough hype - the stock soars f… read more...

Your Daily Pharma Scoop: Recent IPO And Offerings Review

via: SeekingAlpha at 2018-05-31 04:02:59:000

IPO As a general rule, we dont invest in IPOs. It is too risky. What is an IPO but an unknown/unproven business asking for your money to chase some dream of theirs. But many people like dreams, so when an IPO gets launched - assuming theres enough hype - the stock soars f… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika Therapeutics Announces $30 Million Accelerated Share Repurchase

via: Business Wire at 2018-05-23 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced that it will enter into an accelerated share repurchase (ASR)… read more...

Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress

via: Business Wire at 2018-05-08 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced plans to showcase its innovative commercial and pipeline port… read more...

Anika to Showcase Commercial and Pipeline Portfolio at 18th Bi-Annual European Society for Sports Traumatology, Knee Surgery and Arthroscopy Congress

via: Business Wire at 2018-05-08 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology , today announced plans to showcase its innovative commercial and pipeline port… read more...

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

via: SeekingAlpha at 2018-05-08 03:34:11:000

Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu… read more...

Your Daily Pharma Scoop: Synergy Activism, Pfizer Wave Sciences Collaboration, Agenus Update

via: SeekingAlpha at 2018-05-08 03:34:11:000

Analysis focus: SGYP Synergy Pharma (SGYP), ever the laggard, and the bane of many a portfolio, suddenly saw a bit of movement yesterday on the back of news that a group of activist investor s have taken up the cudgel against the management of Synergy. These investors have written to a nu… read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall

via: SeekingAlpha at 2018-05-07 08:00:00:000

Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...

Anika Therapeutics Inc. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-04 14:00:27:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q1 earnings Read more … read more...

Anika Therapeutics Inc. 2018 Q1 - Results - Earnings Call Slides

via: SeekingAlpha at 2018-05-04 14:00:27:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2018 Q1 earnings Read more … read more...

Midday Gainers / Losers (05/03/2018)

via: SeekingAlpha at 2018-05-04 12:58:29:000

Gainers: VVPR +179% . CLWT +71% . IMTE +55% . OTCQB:MKGI +40% . SEII +28% . AMRH +25% . STAA +26% . AMDA +22% . BOXL +20% . NDRA +18% . More news on: VivoPower International PLC, Euro Tech Holdings Company Limited, Integrated Media Technology Limited, … read more...

Midday Gainers / Losers (05/03/2018)

via: SeekingAlpha at 2018-05-04 12:58:29:000

Gainers: VVPR +179% . CLWT +71% . IMTE +55% . OTCQB:MKGI +40% . SEII +28% . AMRH +25% . STAA +26% . AMDA +22% . BOXL +20% . NDRA +18% . More news on: VivoPower International PLC, Euro Tech Holdings Company Limited, Integrated Media Technology Limited, … read more...

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-03 15:14:04:000

Anika Therapeutics Inc. (ANIK) Q1 2018 Earnings Conference Call May 3, 2018 09:00 a.m. ET Executives Joseph Darling - President, Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Lisa Springer - Singular Research Jim Sidot… read more...

Anika Therapeutics Inc. (ANIK) CEO Joseph Darling on Q1 2018 Results - Earnings Call Transcript

via: SeekingAlpha at 2018-05-03 15:14:04:000

Anika Therapeutics Inc. (ANIK) Q1 2018 Earnings Conference Call May 3, 2018 09:00 a.m. ET Executives Joseph Darling - President, Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Lisa Springer - Singular Research Jim Sidot… read more...

Midday Gainers / Losers (05/03/2018)

via: SeekingAlpha at 2018-05-03 12:40:50:000

Gainers: VVPR +179% . CLWT +71% . IMTE +55% . OTCQB:MKGI +40% . SEII +28% . AMRH +25% . STAA +26% . AMDA +22% . BOXL +20% . NDRA +18% . More news on: VivoPower International PLC, Euro Tech Holdings Company Limited, Integrated Media Technology Limited, … read more...

Midday Gainers / Losers (05/03/2018)

via: SeekingAlpha at 2018-05-03 12:40:50:000

Gainers: VVPR +179% . CLWT +71% . IMTE +55% . OTCQB:MKGI +40% . SEII +28% . AMRH +25% . STAA +26% . AMDA +22% . BOXL +20% . NDRA +18% . More news on: VivoPower International PLC, Euro Tech Holdings Company Limited, Integrated Media Technology Limited, … read more...

Anika down 28% on Q1 miss and product recall

via: SeekingAlpha at 2018-05-03 11:33:35:000

Thinly traded small cap Anika Therapeutics ( ANIK -28.1% ) slumps on double normal volume, albeit on turnover of only ~250K shares, after it released Q1 results after the close yesterday. More news on: Anika Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Stock… read more...

Anika down 28% on Q1 miss and product recall

via: SeekingAlpha at 2018-05-03 11:33:35:000

Thinly traded small cap Anika Therapeutics ( ANIK -28.1% ) slumps on double normal volume, albeit on turnover of only ~250K shares, after it released Q1 results after the close yesterday. More news on: Anika Therapeutics Inc., Healthcare stocks news, Earnings news and commentary, Stock… read more...

Anika Therapeutics EPS of -$0.46

via: SeekingAlpha at 2018-05-02 16:21:21:000

Anika Therapeutics (NASDAQ: ANIK ): Q1 EPS of -$0.46 may not be comparable to consensus of $0.16. More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Anika Therapeutics EPS of -$0.46

via: SeekingAlpha at 2018-05-02 16:21:21:000

Anika Therapeutics (NASDAQ: ANIK ): Q1 EPS of -$0.46 may not be comparable to consensus of $0.16. More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...

Anika Reports First Quarter 2018 Financial Results

via: Business Wire at 2018-05-02 16:05:00:000

Successful Leadership Transition in Evolution to a Global Commercial Organization; MONOVISC and CINGAL Global Revenue Increased 38% Year-over-Year; Initiated Voluntary Recall of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integra… read more...

Anika Reports First Quarter 2018 Financial Results

via: Business Wire at 2018-05-02 16:05:00:000

Successful Leadership Transition in Evolution to a Global Commercial Organization; MONOVISC and CINGAL Global Revenue Increased 38% Year-over-Year; Initiated Voluntary Recall of HYALOFAST, HYALOGRAFT-C and HYALOMATRIX Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integra… read more...

Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

via: Business Wire at 2018-02-07 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discus… read more...

Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

via: Business Wire at 2018-02-07 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discus… read more...

Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

via: Business Wire at 2018-02-07 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discus… read more...

Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

via: Business Wire at 2018-02-07 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discus… read more...

Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

via: Business Wire at 2018-02-07 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discus… read more...

Anika to Issue Fourth-Quarter 2017 Financial Results and Business Highlights on Wednesday, February 21

via: Business Wire at 2018-02-07 16:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter 2017 financial results after the close of the market on Wednesday, February 21, 2017 and to hold a conference call the next day, Thursday, February 22, 2018, at 9:00 a.m. ET to discus… read more...

Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis

via: Business Wire at 2018-02-01 16:05:00:000

Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to … read more...

Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis

via: Business Wire at 2018-02-01 16:05:00:000

Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to … read more...

Anika Therapeutics Announces Strategic Collaboration with the Institute of Integrative Biology at the University of Liverpool to Develop an Innovative Therapy for Osteoarthritis

via: Business Wire at 2018-02-01 16:05:00:000

Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced an agreement with the Institute of Integrative Biology at the University of Liverpool to … read more...

Biotech Developer Stock Price Risks & Returns: An Understanding Today

via: SeekingAlpha at 2018-01-30 13:41:33:000

This is not an analysis of the economic, competitive or political fundamentals of this industry group. Instead it is a detailed comparison of the coming near-term price-change prospects for the stocks, based on the up-to-the-day evaluations of experienced and well-informed anal… read more...

Biotech Developer Stock Price Risks & Returns: An Understanding Today

via: SeekingAlpha at 2018-01-30 13:41:33:000

This is not an analysis of the economic, competitive or political fundamentals of this industry group. Instead it is a detailed comparison of the coming near-term price-change prospects for the stocks, based on the up-to-the-day evaluations of experienced and well-informed anal… read more...

Biotech Developer Stock Price Risks & Returns: An Understanding Today

via: SeekingAlpha at 2018-01-30 13:41:33:000

This is not an analysis of the economic, competitive or political fundamentals of this industry group. Instead it is a detailed comparison of the coming near-term price-change prospects for the stocks, based on the up-to-the-day evaluations of experienced and well-informed anal… read more...

Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis

via: Business Wire at 2018-01-24 16:05:00:000

A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeu… read more...

Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis

via: Business Wire at 2018-01-24 16:05:00:000

A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeu… read more...

Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis

via: Business Wire at 2018-01-24 16:05:00:000

A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeu… read more...

Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis

via: Business Wire at 2018-01-24 16:05:00:000

A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeu… read more...

Anika Therapeutics Expands Strategic Collaboration with the Institute for Applied Life Sciences (IALS) at the University of Massachusetts Amherst to Develop Innovative Therapy for Rheumatoid Arthritis

via: Business Wire at 2018-01-24 16:05:00:000

A new agreement to extend a two-year-long strategic collaboration that yielded a promising new modality for the treatment of rheumatoid arthritis (RA) was today announced by Anika Therapeutics, Inc. , (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeu… read more...

Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment

via: Business Wire at 2017-12-27 08:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Adm… read more...

Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment

via: Business Wire at 2017-12-27 08:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Adm… read more...

Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment

via: Business Wire at 2017-12-27 08:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Adm… read more...

Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment

via: Business Wire at 2017-12-27 08:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Adm… read more...

Anika Announces FDA 510(k) Clearance for Its Injectable HA-Based Bone Repair Treatment

via: Business Wire at 2017-12-27 08:05:00:000

Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its HA-based bone void filler received 510(k) clearance from the U.S. Food and Drug Adm… read more...

Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data

via: SeekingAlpha at 2017-12-05 03:50:25:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one … read more...

Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data

via: SeekingAlpha at 2017-12-05 03:50:25:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one … read more...

Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data

via: SeekingAlpha at 2017-12-05 03:50:25:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one … read more...

Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data

via: SeekingAlpha at 2017-12-05 03:50:25:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one … read more...

Your Daily Pharma Scoop: Loxo Data, GW Pharmaceuticals' Q4 Results, Zynerba Positive Data

via: SeekingAlpha at 2017-12-05 03:50:25:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Total Pharma Tracker subscribers get the full version with actionable ideas one … read more...

Flexion - When Approvals Go Bad

via: SeekingAlpha at 2017-10-30 14:51:29:000

Welcome back. We're here to give you a fresh look at the now cratering post-approval on Flexion ( FLXN ). You can read our original bullish piece here . Our original price targets, which hovered around the $35-45 range, were dependent on Flexion getting into the market and being viewed as… read more...

Flexion - When Approvals Go Bad

via: SeekingAlpha at 2017-10-30 14:51:29:000

Welcome back. We're here to give you a fresh look at the now cratering post-approval on Flexion ( FLXN ). You can read our original bullish piece here . Our original price targets, which hovered around the $35-45 range, were dependent on Flexion getting into the market and being viewed as… read more...

Flexion - When Approvals Go Bad

via: SeekingAlpha at 2017-10-30 14:51:29:000

Welcome back. We're here to give you a fresh look at the now cratering post-approval on Flexion ( FLXN ). You can read our original bullish piece here . Our original price targets, which hovered around the $35-45 range, were dependent on Flexion getting into the market and being viewed as… read more...

Flexion - When Approvals Go Bad

via: SeekingAlpha at 2017-10-30 14:51:29:000

Welcome back. We're here to give you a fresh look at the now cratering post-approval on Flexion ( FLXN ). You can read our original bullish piece here . Our original price targets, which hovered around the $35-45 range, were dependent on Flexion getting into the market and being viewed as… read more...

Flexion - When Approvals Go Bad

via: SeekingAlpha at 2017-10-30 14:51:29:000

Welcome back. We're here to give you a fresh look at the now cratering post-approval on Flexion ( FLXN ). You can read our original bullish piece here . Our original price targets, which hovered around the $35-45 range, were dependent on Flexion getting into the market and being viewed as… read more...

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

via: SeekingAlpha at 2017-10-28 09:29:45:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene It has been a disas… read more...

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

via: SeekingAlpha at 2017-10-28 09:29:45:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene It has been a disas… read more...

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

via: SeekingAlpha at 2017-10-28 09:29:45:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene It has been a disas… read more...

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

via: SeekingAlpha at 2017-10-28 09:29:45:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene It has been a disas… read more...

Your Daily Pharma Scoop: Celgene's Big Fall, Tesaro VARUBI Approval, TGTX Midstage Success

via: SeekingAlpha at 2017-10-28 09:29:45:000

This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Analysis of top Seeking Alpha coverage: Celgene It has been a disas… read more...

Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-10-26 14:20:04:000

Anika Therapeutics Inc. (ANIK) Q3 2017 Earnings Conference Call October 26, 2017 9:00 AM ET Executives Charles Sherwood - Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Securities Mike Petusky - Barrington Research Assoc… read more...

Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-10-26 14:20:04:000

Anika Therapeutics Inc. (ANIK) Q3 2017 Earnings Conference Call October 26, 2017 9:00 AM ET Executives Charles Sherwood - Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Securities Mike Petusky - Barrington Research Assoc… read more...

Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-10-26 14:20:04:000

Anika Therapeutics Inc. (ANIK) Q3 2017 Earnings Conference Call October 26, 2017 9:00 AM ET Executives Charles Sherwood - Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Securities Mike Petusky - Barrington Research Assoc… read more...

Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-10-26 14:20:04:000

Anika Therapeutics Inc. (ANIK) Q3 2017 Earnings Conference Call October 26, 2017 9:00 AM ET Executives Charles Sherwood - Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Securities Mike Petusky - Barrington Research Assoc… read more...

Anika Therapeutics' (ANIK) CEO Charles Sherwood on Q3 2017 Results - Earnings Call Transcript

via: SeekingAlpha at 2017-10-26 14:20:04:000

Anika Therapeutics Inc. (ANIK) Q3 2017 Earnings Conference Call October 26, 2017 9:00 AM ET Executives Charles Sherwood - Chief Executive Officer Sylvia Cheung - Chief Financial Officer Analysts Joe Munda - First Analysis Securities Mike Petusky - Barrington Research Assoc… read more...

Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-10-26 09:13:18:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2017 Q3 earnings Read more … read more...

Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-10-26 09:13:18:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2017 Q3 earnings Read more … read more...

Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-10-26 09:13:18:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2017 Q3 earnings Read more … read more...

Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-10-26 09:13:18:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2017 Q3 earnings Read more … read more...

Anika Therapeutics Inc. 2017 Q3 - Results - Earnings Call Slides

via: SeekingAlpha at 2017-10-26 09:13:18:000

The following slide deck was published by Anika Therapeutics Inc. in conjunction with their 2017 Q3 earnings Read more … read more...

Anika Therapeutics misses by $0.01, misses on revenue

via: SeekingAlpha at 2017-10-25 16:16:08:000

Anika Therapeutics (NASDAQ: ANIK ): Q3 EPS of $0.46 misses by $0.01 . Revenue of $27.2M (+5.5% Y/Y) misses by $1.72M . Press Release More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...

Anika Therapeutics misses by $0.01, misses on revenue

via: SeekingAlpha at 2017-10-25 16:16:08:000

Anika Therapeutics (NASDAQ: ANIK ): Q3 EPS of $0.46 misses by $0.01 . Revenue of $27.2M (+5.5% Y/Y) misses by $1.72M . Press Release More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...

Anika Therapeutics misses by $0.01, misses on revenue

via: SeekingAlpha at 2017-10-25 16:16:08:000

Anika Therapeutics (NASDAQ: ANIK ): Q3 EPS of $0.46 misses by $0.01 . Revenue of $27.2M (+5.5% Y/Y) misses by $1.72M . Press Release More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...

Anika Therapeutics misses by $0.01, misses on revenue

via: SeekingAlpha at 2017-10-25 16:16:08:000

Anika Therapeutics (NASDAQ: ANIK ): Q3 EPS of $0.46 misses by $0.01 . Revenue of $27.2M (+5.5% Y/Y) misses by $1.72M . Press Release More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...

Anika Therapeutics misses by $0.01, misses on revenue

via: SeekingAlpha at 2017-10-25 16:16:08:000

Anika Therapeutics (NASDAQ: ANIK ): Q3 EPS of $0.46 misses by $0.01 . Revenue of $27.2M (+5.5% Y/Y) misses by $1.72M . Press Release More news on: Anika Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, read more...

Anika Reports Third Quarter 2017 Financial Results

via: Business Wire at 2017-10-25 16:05:00:000

Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based … read more...

Anika Reports Third Quarter 2017 Financial Results

via: Business Wire at 2017-10-25 16:05:00:000

Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based … read more...

Anika Reports Third Quarter 2017 Financial Results

via: Business Wire at 2017-10-25 16:05:00:000

Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based … read more...

Anika Reports Third Quarter 2017 Financial Results

via: Business Wire at 2017-10-25 16:05:00:000

Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based … read more...

Anika Reports Third Quarter 2017 Financial Results

via: Business Wire at 2017-10-25 16:05:00:000

Completed Enrollment in CINGAL Phase III Clinical Trial; Advancement of Regenerative Medicine Pipeline; MONOVISC Revenue Increased 50% Year-over-Year Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic medicines company specializing in therapeutics based … read more...

Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis

via: Business Wire at 2017-10-25 16:04:00:000

Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL &#xA… read more...

Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis

via: Business Wire at 2017-10-25 16:04:00:000

Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL &#xA… read more...

Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis

via: Business Wire at 2017-10-25 16:04:00:000

Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL &#xA… read more...

Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis

via: Business Wire at 2017-10-25 16:04:00:000

Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL &#xA… read more...

Anika Completes Enrollment in Second Pivotal Phase III Trial of CINGAL for the Treatment of Knee Pain Associated with Osteoarthritis

via: Business Wire at 2017-10-25 16:04:00:000

Anika Therapeutics, Inc . (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced the completion of enrollment in its second pivotal Phase III trial evaluating CINGAL &#xA… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided for free by IEX